- Home
- JTTT vs EQ Comparison
JTTT vs EQ Comparison
Compare JTTT & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JTTT | EQ |
|---|---|---|
| Founded | 2026 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 89.4M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | JTTT | EQ |
|---|---|---|
| Price | $10.52 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.56 |
| AVG Volume (30 Days) | 7.6K | ★ 578.5K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.56 | $1.30 |
| 52 Week High | $11.80 | $6.20 |
Technical Indicators
Market Signals| Indicator | JTTT | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 29.28 |
| Support Level | N/A | $1.30 |
| Resistance Level | $11.15 | $2.53 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 0.14 | 3.57 |
Price Performance
Historical ComparisonAbout JTTT JATT III Acquisition Corp Ordinary Shares
Jatt III Acquisition Corp is a blank check company.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.